Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-01-31
2011-10-11
Cordero Garcia, Marcela M (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000, C530S325000, C530S326000
Reexamination Certificate
active
08034762
ABSTRACT:
Novel ApoE peptide derivatives and ApoE-protein transduction domain conjugates are disclosed which are useful for treating disorders including subarachnoid hemorrhage, intracerebral hemorrhage, and intraventricular hemorrhage and other brain disorders. The invention encompasses methods for treating cerebral vasospasm by administration of at least one ApoE or ApoE mimetic peptide.
REFERENCES:
patent: 4902505 (1990-02-01), Pardridge et al.
patent: 5017566 (1991-05-01), Bodor
patent: 5114956 (1992-05-01), Hoff
patent: 5182364 (1993-01-01), Dyer et al.
patent: 5204327 (1993-04-01), Kiyota et al.
patent: 5473039 (1995-12-01), Dyer et al.
patent: 5604198 (1997-02-01), Poduslo et al.
patent: 5686416 (1997-11-01), Kozarich et al.
patent: 6245751 (2001-06-01), Crutcher et al.
patent: 6472507 (2002-10-01), Fischer et al.
patent: 6605588 (2003-08-01), Lee et al.
patent: 6890902 (2005-05-01), Svendsen et al.
patent: 2002/0164789 (2002-11-01), Laskowitz et al.
patent: 2004/0014652 (2004-01-01), Trouet et al.
patent: WO 92/10512 (1992-06-01), None
patent: WO 95/06456 (1995-03-01), None
patent: WO 97/14437 (1997-04-01), None
patent: WO 98/01101 (1998-01-01), None
patent: WO 99/08701 (1999-02-01), None
patent: WO 99/45950 (1999-09-01), None
patent: WO 03/026479 (2003-04-01), None
patent: WO 03/026479 (2003-04-01), None
Kaspar Binz et al. Engineering novel binding proteins from nonimmunoglobulin domains. Nature Biotechnology. Oct. 2005. vol. 23, No. 10, pp. 1257-1268.
Gaggi et al. Calcitonin enhances the effects of nimodipine on biogenic amines of rat brain. General Pharmacology: The Vascular System. vol. 23, Issue 3, May 1992, pp. 561-563.
Niall et al. Amino acid sequence of salmon ultimobranchial calcitonin. PNAS, Oct. 1, 1969, vol. 64, Nol. 2, pp. 771-778.
Aono, et al., “Protective Effects of Peptides Corresponding to the Receptor Binding Region of Apolipoprotein E on NMDA Excitotoxicity in Primary Neuronal-Glial Cultures”, Trip Report: 31stAnnual Meeting of the Society for Neuroscience, San Diego, California (Nov. 2001).
Barger, et al., “Microglial Activation by Alzheimer Amyloid Precursor Protein and Modulation by Apolipoprotein E”, Nature 388: 878-881 (Aug. 1997).
Benazzouz, et al., “Riluzole Prevents MPTP-induced Parkinsonism in the Rhesus Monkey: A Pilot Study,”Eur. J. Pharmacol. 284:299-307 (1995).
Bowie, et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions”, Science, 247: 1306-1310 (1990).
Cardin, et al., “Inhibition of Lymphocyte Proliferation b Synthetic Peptides Homologous to Human Plasma Apolipoproteins B and E”, Biochemical and Biophysical Research Communications, 154: 741-745 (Jul. 1998).
Champe, et al., “IV. Tertiary Structure of Globular Proteins,” “V. Quaternary Structure of Proteins,” “VI Denaturation of Proteins,” and “VII. Protein Misfolding,” pp. 18-21 inLippincott's Illustrated Reviews: Biochemistry, 3rd Ed. Lippincott Williams & Wilkins, Philadelphia, Pennsylvania, USA (2005).
Chen, et al., “Motor and Cognitive Deficits in Apolipoprotein E Deficient Mice After Closed Head Injury,”Neuroscience80:1255-1262 (1997).
Christie, et al., “Expression of the Very Low-Density Lipoprotein Receptor (VLDL-r), an Apolipoprotein-E Receptor, in the Central Nervous System and in Alzheimer's Disease”, Journal of Neuropathology and Experimental Neurology, 55(4): 491-498 (1996).
Clay, et al., “Localization of a Domain in Apolipoprotein E with Both Cytostatic and Cytotoxic Activity”, Biochemistry, 34: 11142-11151 (1995).
Crutcher, et al., “Neurite degeneration elicited by apolipoprotein E peptides”, Experimental Neurology 130(1):120-126 (1994).
Dong, et al., “Enhanced binding activity of an apolipoprotein E mutant, APO E5, to LDL receptors on human fibroblasts”, Biochemical & Biophysical Research Communications 168(2):409-414 (Apr. 1990).
Dong, et al., “Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3—Lys) and its binding to low density lipoprotein receptors”, Biochemical & Biophysical Research Communications 187(2):1180-1186 (Sep. 1992).
Dyer, et al., “A Synthetic Peptide Mimetic of Plasma Apolipoprotein E that Binds the LDL Receptor”, Journal of Biological Chemistry, 266: 22803-22806 (Dec. 1991).
Dyer, et al., “Only Multimers of a Synthetic Peptide of Human Apolipoprotein E Are Biologically Active”, Journal of Biological Chemistry, 266: 15009-15015 (1991).
Gao, et al., “A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage”, Neurocritical Care, 4:25-31 (2006).
Gordon, et al., “Derangement in Stress Response of Apolipoprotein E-deficient Mice,”Neuroscience Letters206:212-214 (1996).
Holtzman, et al., “Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line”, Proc. Natl. Acad. Sci. USA, 92: 9480-9484 (1995).
Innerarity, et al., “Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts”, Journal of Biological Chemistry 254(10):4186-4190 (1979).
International Search Report for PCT/US99/05221 (mailed Nov. 3, 1999).
Jordan, et al., “Isoform-Specific Effect of Apolipoprotein E on Cell Survival and β-Amyloid-induced Toxicity in Rat Hippocampal Pyramidal Neuronal Cultures,”J. Neurosci. 18:195-204 (1998).
Lalazar, et al., “Site-specific Mutagenesis of Human Apolipoprotein E”, Journal of Biological Chemistry, 263: 3542-3545 (1988).
Lanterna, et al., “APOE influences vasospasm and cognition of non-comatose patients with subarachnoid hemorrhage”, Neurology, 64:1238-1244 (2005).
Laskowitz, et al., “Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production”, Neuroreport. 9(4):615-618 (1998).
Laskowitz, et al., “Apolipoprotein E and the CNS response to injury”, Journal of Cerebral Blood Flow & Metabolism 18(5): 465-471 (1998).
Laskowitz, et al., “Apolipoprotein E suppresses glial cell secretion of TNF alpha”, Journal of Neuroimmunology 76(1-2):70-74, (1997).
Laskowitz, et al., “Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia”, Journal of Cerebral Blood Flow & Metabolism 17(7):753-758 (1997).
Laskowitz, et al., “Downregulation of Microglial Activation by Apolipoprotein E and ApoE-Mimetic Peptide”, Experimental Neurology, 167: 74-85 (2001).
Leung et al., “Apolipoprotein E genotype and outcome in aneurysmal subarachnoid hemorrhage”, Stroke, 33:548-552 (2002).
Ludwig, “Supplementary European Search Report,” 3 pages, from EP Appl. No. 02775888.7, European Patent Office, Munich, Germany (mailed Mar. 9, 2007).
Lynch et al., “APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory Response”, Journal of Biological Chemistry, 278(4): 48529-33 (2003).
Lynch et al., “A novel therapeutic derived from apolipoprotein E reduces brain inflammation and improves outcome after closed head injury”, Experimental Neurology, 192:109-116 (2005).
Marzolo, et al., “Expression of α2-Macroglobulin Receptor/ Low Density Lipoprotein Receptor-Related Protein (LRP) in Rat Microglial Cells,” Journal of Neuroscience Research, 60:401-411 (2000).
Mesis et al., “Dissociation between Vasospasm and Functional Improvement in a Murine Model of Subarachnoid Hemorrhage”, Neurosurgical Foucs, 21: 1-7 (2006).
Mickle, et al., “Genotype-phenotype relationships in cystic fibrosis”, Med. Clin. North Am., 84 (3): 597-607 (May 2000).
Misra, et al., “Apolipoprotein E and Mimetic Peptide Ini
Laskowitz Daniel T.
Vitek Michael P.
Cognosci, Inc.
Cooley LLP
Cordero Garcia Marcela M
LandOfFree
Treatment of subarachnoid hemorrhage with Apo E analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of subarachnoid hemorrhage with Apo E analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of subarachnoid hemorrhage with Apo E analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4295977